{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T20:45:42Z","timestamp":1785876342325,"version":"3.56.0"},"reference-count":22,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"8","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO Precis Oncol"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:sec>\n                    <jats:title>PURPOSE<\/jats:title>\n                    <jats:p>\n                      TRK inhibitors (TRKis) have transformed the therapeutic landscape for patients with neurotrophic tyrosine receptor kinase (\n                      <jats:italic toggle=\"yes\">NTRK<\/jats:italic>\n                      ) gene fusion\u2013positive tumors. However, approval of TRKis is based on evidence derived mainly from small, pooled, single-arm clinical trial cohorts. The REALTRK registry aims to describe real-world molecular diagnostic practices, treatment patterns, and clinical outcomes for adult patients with\n                      <jats:italic toggle=\"yes\">NTRK<\/jats:italic>\n                      fusion\u2013positive cancers.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PATIENTS AND METHODS<\/jats:title>\n                    <jats:p>\n                      The REALTRK registry was a multicenter cohort study that included adults with advanced solid tumors harboring\n                      <jats:italic toggle=\"yes\">NTRK1<\/jats:italic>\n                      \/\n                      <jats:italic toggle=\"yes\">2<\/jats:italic>\n                      \/\n                      <jats:italic toggle=\"yes\">3<\/jats:italic>\n                      fusions, from Germany and Switzerland. Both retrospective and prospective data were collected from diverse clinical settings.\n                      <jats:italic toggle=\"yes\">NTRK<\/jats:italic>\n                      fusions had to be diagnosed via validated assays.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>\n                      Of 88 patients screened, 47 adults with advanced\n                      <jats:italic toggle=\"yes\">NTRK<\/jats:italic>\n                      fusion\u2013positive solid tumors were included in the full analysis set. Across all treatment lines after\n                      <jats:italic toggle=\"yes\">NTRK<\/jats:italic>\n                      fusion diagnosis, 29 patients received TRKi therapy, eight received non-TRKi therapy, and 10 received no therapy. Lung cancer, colorectal cancer, and soft tissue sarcoma were the most common tumor types. Next-generation sequencing was the primary diagnostic method, with a median turnaround time of 2 weeks. After\n                      <jats:italic toggle=\"yes\">NTRK<\/jats:italic>\n                      fusion diagnosis, TRKi therapy was immediately initiated in 26 patients, of whom 13 received TRKi as first-line treatment in the advanced\/metastatic setting. About half of the patients responded to TRKi treatment as the first treatment line after\n                      <jats:italic toggle=\"yes\">NTRK<\/jats:italic>\n                      fusion diagnosis (46.2%), with an overall response rate of 46.2% and a disease control rate of 73.1%. The median progression-free survival was 15.7 months, and the overall survival was 27.6 months in TRKi-treated patients.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>\n                      The REALTRK registry provides important real-world insights into the patient path of adult patients with locally advanced or metastatic solid tumors harboring\n                      <jats:italic toggle=\"yes\">NTRK1<\/jats:italic>\n                      \/\n                      <jats:italic toggle=\"yes\">2<\/jats:italic>\n                      \/\n                      <jats:italic toggle=\"yes\">3<\/jats:italic>\n                      gene fusions.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/po-26-00283","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T19:59:13Z","timestamp":1785873553000},"update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":0,"title":["Real-World Evidence for Oncology Patients With Rare\n                    <i>NTRK<\/i>\n                    Gene Fusions: Final Results From the German Multicenter Patient Cohort Study REALTRK"],"prefix":"10.1200","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1015-9624","authenticated-orcid":true,"given":"Karin","family":"Potthoff","sequence":"first","affiliation":[{"name":"Medical Department, iOMEDICO, Freiburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0406-1401","authenticated-orcid":true,"given":"Sebastian","family":"Lange","sequence":"additional","affiliation":[{"name":"Clinical Department of Internal Medicine II, TUM School of Medicine and Health, TUM University Hospital, Munich, Germany"},{"name":"Center for Personalized Medicine, TUM School of Medicine and Health, TUM University Hospital, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3259-0810","authenticated-orcid":true,"given":"Thomas","family":"Seufferlein","sequence":"additional","affiliation":[{"name":"Universit\u00e4tsklinikum Ulm, Klinik f\u00fcr Innere Medizin I, Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3580-2313","authenticated-orcid":true,"given":"Kathrin","family":"Heinrich","sequence":"additional","affiliation":[{"name":"LMU Klinikum, Medizinische Klinik und Poliklinik III, M\u00fcnchen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2617-8766","authenticated-orcid":true,"given":"Rainer","family":"Claus","sequence":"additional","affiliation":[{"name":"University of Augsburg, Faculty of Medicine, Comprehensive Cancer Center Augsburg (CCCA), Augsburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5809-9507","authenticated-orcid":true,"given":"Annalen","family":"Bleckmann","sequence":"additional","affiliation":[{"name":"Universit\u00e4tsklinikum M\u00fcnster, Medizinische Klinik A, M\u00fcnster, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Zaiss","sequence":"additional","affiliation":[{"name":"Praxis f\u00fcr interdisziplin\u00e4re Onkologie &amp; H\u00e4matologie, Freiburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne","family":"Vannier","sequence":"additional","affiliation":[{"name":"Medical Department, iOMEDICO, Freiburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sina","family":"Grebhardt","sequence":"additional","affiliation":[{"name":"Clinical Operations, iOMEDICO, Freiburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Koszinowski","sequence":"additional","affiliation":[{"name":"Medical Department, iOMEDICO, Freiburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larissa E.","family":"Hillebrand","sequence":"additional","affiliation":[{"name":"Medical Department, iOMEDICO, Freiburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5886-6745","authenticated-orcid":true,"given":"Kai","family":"Ringwald","sequence":"additional","affiliation":[{"name":"Biostatistics, iOMEDICO, Freiburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Kasenda","sequence":"additional","affiliation":[{"name":"Universit\u00e4tsspital Basel, Medizinische Onkologie, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_10_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmoldx.2019.03.008"},{"key":"e_1_3_10_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-019-0324-7"},{"key":"e_1_3_10_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-021-00913-8"},{"key":"e_1_3_10_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-31055-3"},{"key":"e_1_3_10_6_2","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2023.2274426"},{"key":"e_1_3_10_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30856-3"},{"key":"e_1_3_10_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30691-6"},{"key":"e_1_3_10_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz204"},{"key":"e_1_3_10_10_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-3597"},{"key":"e_1_3_10_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1714448"},{"key":"e_1_3_10_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy424.017"},{"key":"e_1_3_10_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-57941-0"},{"key":"e_1_3_10_14_2","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2024.30.7.672"},{"key":"e_1_3_10_15_2","doi-asserted-by":"publisher","unstructured":"Lassen U Bokemeyer C Garcia-Foncillas J et al: Prognostic value of neurotrophic tyrosine receptor kinase gene fusions in solid tumors for overall survival: A systematic review and meta-analysis. JCO Precis Oncol 10.1200\/PO.22.00651","DOI":"10.1200\/PO.22.00651"},{"key":"e_1_3_10_16_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.3105"},{"key":"e_1_3_10_17_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16193395"},{"key":"e_1_3_10_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-022-00909-7"},{"key":"e_1_3_10_19_2","doi-asserted-by":"publisher","unstructured":"Brose MS Westphalen CB Pan X et al: Larotrectinib compared with real-world non\u2013tropomyosin receptor kinase inhibitor therapies in patients with tropomyosin receptor kinase fusion cancer. JCO Precis Oncol 10.1200\/PO-24-00500","DOI":"10.1200\/PO-24-00500"},{"key":"e_1_3_10_20_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0270571"},{"key":"e_1_3_10_21_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-023-00950-0"},{"key":"e_1_3_10_22_2","doi-asserted-by":"publisher","DOI":"10.1200\/OP.22.00260"},{"key":"e_1_3_10_23_2","doi-asserted-by":"publisher","unstructured":"Nichetti F Brambilla M Duca M et al: Real-world outcomes of molecular tumor board treatment recommendations. JCO Precis Oncol 10.1200\/PO-24-00387","DOI":"10.1200\/PO-24-00387"}],"container-title":["JCO Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/PO-26-00283","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T19:59:13Z","timestamp":1785873553000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/PO-26-00283"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":22,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10.1200\/PO-26-00283"],"URL":"https:\/\/doi.org\/10.1200\/po-26-00283","relation":{},"ISSN":["2473-4284"],"issn-type":[{"value":"2473-4284","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"2026-03-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-29","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-10","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e2600283"}}